Clinical Trial Update: A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine [Phase 1]

View source ↗

Summary

Phase Ib trial assessing safety, tolerability, and preliminary efficacy of LY2780301 in combination with gemcitabine in solid tumors and non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• Gemcitabine (Gemcitabine)
• LY2780301 (LY2780301)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Solid Tumors and Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED